Intellia Therapeutics Inc [NTLA] stock is trading at $9.30, down -1.69%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NTLA shares have gain 2.25% over the last week, with a monthly amount drifted -5.01%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on March 05, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $30. Previously, JP Morgan downgraded its rating to Neutral on February 28, 2025, and dropped its price target to $13. On February 28, 2025, downgrade downgraded it’s rating to Sell but maintained its price target of $9 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and decreased its price target to $11 on January 27, 2025. Goldman downgraded its rating to a Neutral and reduced its price target to $32 on February 23, 2024. In a note dated April 13, 2023, Canaccord Genuity initiated an Buy rating and provided a target price of $66 on this stock.
Intellia Therapeutics Inc [NTLA] stock has fluctuated between $8.30 and $31.10 over the past year. Currently, Wall Street analysts expect the stock to reach $28.25 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $9.30 at the most recent close of the market. An investor can expect a potential return of 203.76% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
Intellia Therapeutics Inc [NASDAQ:NTLA] reported sales of 57.88M for the trailing twelve months, which represents a growth of 771.57%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -9.23%, Pretax Profit Margin comes in at -8.97%, and Net Profit Margin reading is -8.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.54 and Total Capital is -0.49. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.70 points at the first support level, and at 8.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.85, and for the 2nd resistance point, it is at 10.39.
Ratios To Look Out For
For context, Intellia Therapeutics Inc’s Current Ratio is 5.77. In addition, the Quick Ratio stands at 5.77 and the Cash Ratio stands at 1.71. Considering the valuation of this stock, the price to sales ratio is 16.63, the price to book ratio is 1.09.
Transactions by insiders
Recent insider trading involved Clark Eliana, EVP, Chief Technical Officer, that happened on Mar 04 ’25 when 679.0 shares were sold. EVP, General Counsel, BASTA JAMES completed a deal on Mar 04 ’25 to sell 2572.0 shares. Meanwhile, Director Bhanji Muna sold 265.0 shares on Jan 29 ’25.
